US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Militia Long/Short Equity ETF

29.90

-0.0194-0.06%

Post-market: 29.82-0.0789-0.26%16:11 EDT

Volume:23.58K

Turnover:704.84K

Market Cap:- -

PE:- -

High:30.25

Open:30.25

Low:29.82

Close:29.92

Loading ...

Overview Company News Filings

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

Press Release: Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

Press Release: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Press Release: Immatics Announces First Quarter 2025 Financial Results and Business Update

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":29.8989,"timestamp":1753473600000,"preClose":29.9183,"halted":0,"volume":23581,"hourTrading":{"tag":"盘后","latestPrice":29.82,"preClose":29.8989,"latestTime":"16:11 EDT","volume":1,"amount":29.8989,"timestamp":1753474319150},"delay":0,"floatShares":3280000,"shares":0,"eps":0,"marketStatus":"Closed","change":-0.0194,"latestTime":"07-25 16:00:00 EDT","open":30.25,"high":30.25,"low":29.82,"amount":704841.1104,"amplitude":0.014372,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":29.9183,"sharesOutstanding":3280000,"nav":29.96,"aum":98268800,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.82,"preClose":29.8989,"latestTime":"16:11 EDT","volume":1,"amount":29.8989,"timestamp":1753474319150},"volumeRatio":0.66982},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":3280000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.66982,"shares":0,"dividePrice":0,"high":30.25,"amplitude":0.014372,"preClose":29.9183,"low":29.82,"week52Low":25.63,"pbRate":"--","week52High":30.57,"institutionHeld":0,"latestPrice":29.8989,"eps":0,"divideRate":0,"volume":23581,"delay":0,"ttmEps":0,"open":30.25,"prevYearClose":25.88,"prevWeekClose":28.7957,"prevMonthClose":29.28,"prevQuarterClose":29.28,"fiveDayClose":28.7957,"twentyDayClose":29.11,"sixtyDayClose":27.48},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553521798","title":"Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2553521798","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553521798?lang=en_us&edition=fundamental","pubTime":"2025-07-23 19:00","pubTimestamp":1753268400,"startTime":"0","endTime":"0","summary":"REHOVOT, Israel, July  23, 2025  (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (\"Purple Biotech\" or \"the Company\") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/23/3120090/0/en/Purple-Biotech-CEO-Issues-Letter-to-Shareholders-Highlighting-Pipeline-Progress-and-Clinical-Milestones-Achieved-in-First-Half-of-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4097","BK4211","BK4225","BK4161","ITT","LU0054578231.USD","ORR","PFS","OS","PRGS","LU0053671581.USD","LU2065732104.USD","HR","BK4203"],"gpt_icon":0},{"id":"2552995694","title":"European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2552995694","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552995694?lang=en_us&edition=fundamental","pubTime":"2025-07-18 23:30","pubTimestamp":1752852600,"startTime":"0","endTime":"0","summary":"– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –STAMFORD, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/18/3118039/0/en/European-Commission-Grants-Conditional-Approval-of-EZMEKLY-mirdametinib-for-the-Treatment-of-Adult-and-Pediatric-Patients-with-NF1-PN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","BK4201","ORR","BK4096","EC","PN"],"gpt_icon":0},{"id":"2551128305","title":"Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2551128305","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551128305?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:00","pubTimestamp":1752667200,"startTime":"0","endTime":"0","summary":"Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/16/3116333/0/en/Cue-Biopharma-Reports-New-Complete-Response-and-Confirmed-50-Overall-Response-Rate-in-Ongoing-Phase-1-Trial-of-CUE-101-and-Pembrolizumab-in-Recurrent-Metastatic-HPV-Head-and-Neck-C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","CUE","BK4161","ORR","PR","BK4124","BK4139","CPS","BK4213","OS","BK4097"],"gpt_icon":0},{"id":"2551216465","title":"SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2551216465","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551216465?lang=en_us&edition=fundamental","pubTime":"2025-07-15 19:45","pubTimestamp":1752579900,"startTime":"0","endTime":"0","summary":"The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/15/3115485/0/en/SELLAS-Meets-All-Primary-Endpoints-in-Phase-2-Trial-of-SLS009-in-r-r-AML-and-Receives-FDA-Guidance-to-Advance-into-First-Line-Therapy-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OS","ORR","SLS","BK4097"],"gpt_icon":0},{"id":"2551697271","title":"Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2551697271","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551697271?lang=en_us&edition=fundamental","pubTime":"2025-07-15 19:00","pubTimestamp":1752577200,"startTime":"0","endTime":"0","summary":"- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/15/3115441/0/en/Adagene-Announces-Regulatory-Update-on-Clinical-Development-Plan-for-Muzastotug-in-Microsatellite-Stable-Colorectal-Cancer-Following-Productive-Type-B-End-of-Phase-1-Meeting-with-F.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2461242641.AUD","IE00BJT1NW94.SGD","LU1430594728.SGD","IE0002141913.USD","LU0320765489.SGD","LU1929549753.HKD","LU0965509283.SGD","LU0965509101.SGD","LU1917777945.USD","OS","LU0289739699.SGD","LU0320765646.SGD","LU1023059063.AUD","SG9999002224.SGD","LU2361045086.USD","BK4195","IE00BBT3K403.USD","BK4550","IE00B1BXHZ80.USD","LU0211331839.USD","LU0266013472.USD","LU1066051225.USD","LU1934455194.USD","LU1066053197.SGD","LU0106261372.USD","LU1066051811.HKD","ORR","SG9999001176.USD","BK4534","ADAG","CRC","LU1983299246.USD","SOC","PFS","LU1934455863.HKD","MSS","LU1941712264.USD","LU1061106388.HKD","MRK","SG9999014559.SGD","LU1699723380.USD","IE00BSNM7G36.USD","LU2112291526.USD","SG9999014542.SGD","LU0266512127.USD","SG9999015358.SGD","BK4211","LU1066051498.USD","LU0265550359.USD","LU2324357040.USD"],"gpt_icon":0},{"id":"2551218324","title":"Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2551218324","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551218324?lang=en_us&edition=fundamental","pubTime":"2025-07-14 19:30","pubTimestamp":1752492600,"startTime":"0","endTime":"0","summary":"61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July  14, 2025  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/14/3114660/0/en/Real-World-Data-Demonstrate-a-49-Response-Rate-for-Commercial-Amtagvi-in-Patients-with-Advanced-Melanoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA","ORR","IE00B7SZL793.SGD","TIL","AEIS","BK4505","BK4157","IE00B66KJ199.SGD","IE0031619046.USD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2550625666","title":"Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=2550625666","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550625666?lang=en_us&edition=fundamental","pubTime":"2025-07-10 21:30","pubTimestamp":1752154200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, July  10, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in can","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/10/3113419/0/en/Ascentage-Pharma-Announces-Its-Novel-Bcl-2-Inhibitor-Lisaftoclax-Approved-by-China-NMPA-Ushering-in-a-New-Era-for-the-Treatment-of-CLL-SLL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","IE00BVYPNV92.GBP","LU1221951129.SGD","LU1267930813.SGD","ORR","SG9999015952.SGD","BK4581","LU0203345920.USD","LU1059921491.USD","LU2506952170.USD","LU1883839398.USD","SG9999015945.SGD","AAPG","LU1506573853.SGD","IE00B3T34201.USD","SG9999001440.SGD","LU2506951875.HKD","LU0203347892.USD","IE00BVYPNW00.USD","LU2237443978.SGD","LU0889566641.SGD","SG9999015986.USD","BK4515","LU2286300806.USD","PPI","BK4533","BK4139","BK4097","LU0348723411.USD","TLS","LU2247934214.USD","BK4570","SG9999015978.USD","LU1046421795.USD","LU2237443549.SGD","LU0234572021.USD","CSCO","BK4588","LU1221951046.USD","LU1244550577.SGD","LU1066051498.USD","SG9999002232.USD","LU1880398471.USD","SG9999002224.SGD","LU0823417653.USD","LU0950375773.USD","LU2237443465.HKD","LU1894683264.USD","BK4525","LU1894683348.USD"],"gpt_icon":0},{"id":"2550766821","title":"Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2550766821","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550766821?lang=en_us&edition=fundamental","pubTime":"2025-07-10 04:01","pubTimestamp":1752091260,"startTime":"0","endTime":"0","summary":"Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and W","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112864/0/en/Nurix-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1923621640.USD","LU0175139822.USD","LU0347712357.USD","LU0456855351.SGD","WM","LU0689626769.HKD","LU1066053197.SGD","LU1066051498.USD","IE00B19Z3B42.SGD","CR","BK4585","IE00B19Z3581.USD","IE0009354923.USD","SG9999002224.SGD","BK4599","LU1917777945.USD","LU2229751404.USD","LU2023250504.SGD","LU2240825500.USD","NRIX","LU2355687059.USD","LU0058720904.USD","BK4581","LU1989772840.SGD","IE00BLSP4452.SGD","LU1712237335.SGD","LU0321505439.SGD","LU1892829315.USD","LU0289960550.SGD","LU2092937221.SGD","ODD","LU2298064838.USD","EMA","LU2023250843.SGD","LU2211814178.USD","LU0289961442.SGD","LU0306807586.USD","LU1023059063.AUD","LU2413666426.HKD","LU1894683348.USD","ORR","SG9999013999.USD","BK4588","LU2362541513.USD","SGXZ57979304.SGD","CNS","LU2041044095.USD","BK4566"],"gpt_icon":1},{"id":"2549391075","title":"BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2549391075","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549391075?lang=en_us&edition=fundamental","pubTime":"2025-07-07 19:00","pubTimestamp":1751886000,"startTime":"0","endTime":"0","summary":"In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3110902/0/en/BeyondSpring-Publishes-Human-Clinical-Study-in-Med-Cell-Press-Showing-Plinabulin-Driven-Dendritic-Cell-Maturation-and-Tumor-Response-After-Prior-Checkpoint-Inhibitor-Failure.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DC","BK4139","ORR","BYSI","BK4017"],"gpt_icon":0},{"id":"2540737112","title":"Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540737112","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540737112?lang=en_us&edition=fundamental","pubTime":"2025-06-02 01:12","pubTimestamp":1748797920,"startTime":"0","endTime":"0","summary":"Median DOR of 21.7 months with 80% of responders achieving a deep response . Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC. Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET. In the Phase 1/1b trial, ficerafusp alfa in combination with pembrolizumab resulted in deep and durable anti-tumor activity with improved overall survival  compared to historical benchmarks in patients with 1L R/M human papillomavirus-negative HNSCC with a PD-L1 combined positive score  of ≥1 and with at least 24 months of follow-up.In the efficacy evaluable human papillomavirus-negative population :. Median OS of 21.3 months; 2-year OS rate of 46%.54%  confirmed objective response rate ; 64%  ORR, including an additional three unconfirmed responses.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicara-therapeutics-demonstrates-deep-durable-171200341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4124","BK4097","BK4139","ORR","BCAX","CPS"],"gpt_icon":0},{"id":"2539830210","title":"Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2539830210","media":"Insider Monkey","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539830210?lang=en_us&edition=fundamental","pubTime":"2025-05-30 03:48","pubTimestamp":1748548115,"startTime":"0","endTime":"0","summary":"Merck KGaA  is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour . The MANEUVER trial, conducted with Abbisko Therapeutics, showed a 61.9% overall response rate  by tumour volume score  after 25 weeks, far surpassing placebo . This efficacy outperformed Daiichi Sankyo’s Turalio  and was just behind Ono Pharmaceutical’s Romvimza , which received FDA approval in February 2025.Quality of life improvements were notable, with significant gains in range of movement, stiffness, and pain reduction. Importantly, pimicotinib demonstrated a favorable safety profile: while all patients experienced some adverse events, only 4.8% were serious, and there were no signs of liver toxicity, a key differentiator from other therapies.TGCT, a rare non-cancerous joint tumour, often recurs after surgery, making effective drug options crucial. Merck KGaA , having secured global rights from Abbisko in March 2025, has f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-co-inc-mrk-files-042935298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999002224.SGD","MKGAF","IE00BLSP4239.USD","LU1974910355.USD","IE0009355771.USD","LU2361044949.HKD","LU0106261372.USD","LU1061106388.HKD","ORR","LU2468319806.SGD","LU0985320562.USD","SG9999014559.SGD","IE00BBT3K403.USD","LU1066051498.USD","LU1917777945.USD","LU0965508806.USD","LU1116320737.USD","LU0266013472.USD","LU0070302665.USD","LU1037948897.HKD","LU1066051225.USD","LU1430594728.SGD","LU2461242641.AUD","SG9999001440.SGD","LU1934455277.USD","LU0965509283.SGD","IE0002141913.USD","LU2324357040.USD","LU0208291251.USD","LU1989771016.USD","MRK","BK4588","LU1941712264.USD","LU0006306889.USD","IE000M9KFDE8.USD","III","LU1291159041.SGD","IE00B4R5TH58.HKD","BK4559","LU0265550946.USD","LU1585245621.USD","LU1069347547.HKD","SG9999013999.USD","LU0965509010.AUD","IE00BLSP4452.SGD","LU0861579265.USD","IE00B1BXHZ80.USD","LU2089984988.USD","BK4007","LU2361044865.SGD"],"gpt_icon":0},{"id":"2539296289","title":"AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2539296289","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539296289?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:00","pubTimestamp":1748350800,"startTime":"0","endTime":"0","summary":"-  Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates  including telisotuzumab adizutecan  in advanced non-small cell lung cancer , ABBV-706 in high-grade neuroendocrine neoplasms  and pivekimab sunirine  in blastic plasmacytoid dendritic cell neoplasm .NORTH CHICAGO, Ill., May 27, 2025 /PRNewswire/ -- AbbVie  today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology  Annual Meeting . These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers.\"The data we're presenting at this year's ASCO reflect the breadth and depth of our oncology pipeline and our unwavering commitment to research that could transform outcomes for patients facing cancer,\" said Roopal Thakkar, M.D., executive vice president, research and development an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-features-data-across-difficult-130000579.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-features-data-across-difficult-130000579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443895.HKD","LU1267930490.SGD","LU2133065610.SGD","CR","LU0029864427.USD","CRC","LU2129689514.USD","LU2468319806.SGD","ORR","LU0234570918.USD","LU1162221912.USD","IE0002141913.USD","LU0882574055.USD","CCR","IE0002270589.USD","LU0965509101.SGD","IE00B3PB1722.GBP","BK4585","IE0004445239.USD","BK4581","LU2089984988.USD","LU1551013425.SGD","LU1037948541.HKD","LU2087621335.USD","LU0122379950.USD","LU0795875086.SGD","LU1934455194.USD","LU1093756325.SGD","IE00BJT1NW94.SGD","BK4566","ADC","LU0114720955.EUR","SG9999001440.SGD","SG9999015945.SGD","LU0545039389.USD","LU1430594728.SGD","LU2112291526.USD","LU1989772923.USD","LU0912757837.SGD","LU0943347566.SGD","MT","LU1037948897.HKD","IE00B19Z3581.USD","BK4213","LU1496350502.SGD","LU1934455863.HKD","IE00B19Z3B42.SGD","ABBV","LU1989771016.USD"],"gpt_icon":0},{"id":"2536373266","title":"Press Release: Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2536373266","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536373266?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:01","pubTimestamp":1747684860,"startTime":"0","endTime":"0","summary":"- Interim Jan-2025 results from three trials of Alpha DaRT in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -. - 75% systemic objective response rate  and 37.5% complete response rate meaningfully higher thus far than historical Keytruda monotherapy data in Jan-2025 interim read out of a combination trial of Alpha DaRT and Keytruda in head and neck squamous cell carcinoma  -. - FDA approval of Investigational Device Exemption  and IDE supplement to conduct a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with newly diagnosed locally advanced or metastatic pancreatic cancer -. - FDA approval of IDE to conduct a U.S. pilot study of Alpha DaRT in patients with recurrent glioblastoma multiforme , a highly aggressive brain cancer -","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","DRTS","BK4022","BK4082","IDE","R","ORR"],"gpt_icon":0},{"id":"2535025235","title":"Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025235","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025235?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:00","pubTimestamp":1747224000,"startTime":"0","endTime":"0","summary":"LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress  and the 18 International Conference on Malignant Lymphoma ; ZYNLONTA plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability. Cash runway expected to fund multiple catalysts into the second half of 2026. LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates.\"We are encouraged by the promising LOTIS-7 abstract data, which we believe demonstrate the potential for ZYNLONTA plus glofitamab to be a best-in-class combination in a dynamic market,\" said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. \"Coupled with the progress of our LOTIS-5 confirmatory trial, we are confident in our path forward and the potential of ZYNLON","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","PBD","BK4161","BK4080","BK4211","BK4007","BK4139","BK4232","BK4505","ORR","LENZ","ADC","R","BK4022","BK4195","ADCT","CR","BK4539","BK4231"],"gpt_icon":0},{"id":"2535084331","title":"Press Release: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535084331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535084331?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166700,"startTime":"0","endTime":"0","summary":"-- SLS009 Shows Promising Efficacy in Pediatric Acute Lymphoblastic Leukemia  Xenograft Models --. -- Final Analysis of Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in AML Anticipated in 2025 --. -- $28.4 million in Cash and Cash Equivalents as of March 31, 2025; Additional $4.0 million Proceeds received in April 2025 through Warrant Exercises --. NEW YORK, May 13, 2025  -- SELLAS Life Sciences Group, Inc.  , a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.Presented Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference: Preclinical data suggest tha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4585","BK4097","BK4161","BK4139","BK4213","OS","ALL","BK4107","CR","LU1699723380.USD","ORR","LU0985320562.USD","BK4232","BK4022","BK4588","PR","BK4533","LU1571399168.USD","LU2355687059.USD","R","PDX"],"gpt_icon":0},{"id":"2535726182","title":"Press Release: Immatics Announces First Quarter 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535726182","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535726182?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:00","pubTimestamp":1747134000,"startTime":"0","endTime":"0","summary":"-- IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME,in previously treated advanced melanoma ongoing and expected to complete. data in metastatic melanoma with substantially longer follow-up and. additional uveal melanoma patients to be presented in an oral. -- IMA203CD8 PRAME Cell Therapy : Phase 1a clinical trial in solid. -- IMA402 PRAME Bispecific: Phase 1a clinical trial in solid tumors ongoing. -- Combination of IMA203 PRAME cell therapy and Moderna's PRAME adaptive. -- IMA401 MAGEA4/8 Bispecific: Phase 1a clinical trial, including a. IMA203 is Immatics' lead PRAME cell therapy, currently being evaluated in a Phase 3 trial  in patients with previously treated advanced melanoma. IMA203 has the potent","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4195","IMTX","PFS","BK4211","ORR","OS","BK4097"],"gpt_icon":0},{"id":"2532858279","title":"Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2532858279","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532858279?lang=en_us&edition=fundamental","pubTime":"2025-05-02 08:24","pubTimestamp":1746145440,"startTime":"0","endTime":"0","summary":"Decision to submit based on a positive overall response rate  , one of the dual primary endpoints in the Phase 3 EPCORE FL-1 trial. The decision to submit the sBLA is supported by positive topline results from the Phase 3 EPCORE FL-1 trial evaluating epcoritamab plus R2 versus R2 alone in adult patients with R/R FL. Based on an interim analysis conducted by an Independent Data Monitoring Committee  review, the study met one of its dual primary endpoints of ORR . The safety profile of epcoritamab plus R2 in adult patients with R/R FL was consistent with the known safety profiles of the individual regimens  and as presented in the U.S. prescribing information for epcoritamab. No new safety signals were observed. The full results will be submitted later this year for presentation at an upcoming medical congress and discussed with global regulatory authorities.About Follicular Lymphoma FL is typically an indolent  form of non-Hodgkin's lymphoma  that arises from B-lymphocytes and is the se","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genmab-submit-supplemental-biologics-license-002400918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4094","CRS","ORR","IE0031619046.USD","FL","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4139","BK4588","GMAB","IE00B66KJ199.SGD","BK4585","BK4006","LU2065731478.USD"],"gpt_icon":0},{"id":"2531203126","title":"CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531203126","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531203126?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:15","pubTimestamp":1746015300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April 30, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute , in Nashville, Tennessee, is a clinical trial site for the Company’s Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia , and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","ORR","CERO","BK4218","PK","BK4181","BK4139","CEROW","BK4161"],"gpt_icon":0},{"id":"2531392850","title":"Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups","url":"https://stock-news.laohu8.com/highlight/detail?id=2531392850","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531392850?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"Statistically significant efficacy in biomarker subgroup analyses was observed:. 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup. 61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase  subgroup. 90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score  subgroup. The biomarkers identified in the Phase 2 study are planned to be used for patient selection in the next Phase 2b study. Prolongation of 2.4 months in OS HR=0.81  and prolongation of 1.9 months in PFS HR=0.75  vs. control arm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/purple-biotech-reports-final-data-110000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4565","BK4560","BK4124","BK4535","BK4097","PPBT","BK4548","BK4571","IE00BYTNYN87.SGD","TME","SG9999011746.SGD","BK4509","BK4116","OS","BK4613","NET","ORR","BK4552","BK4195","BK4563","BK4007","LU2286300806.USD","LU1023057109.AUD","LU2039709279.SGD","BK4607","LU0359201612.USD","BK4588","IE00B12V2V27.USD","01698","BK4211","LU0359202008.SGD","BK4108","BK4526","BK4531","IE00BYQNZ168.SGD","PFS","BK4554","CPS"],"gpt_icon":0},{"id":"2531759499","title":"Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531759499","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531759499?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:00","pubTimestamp":1745935200,"startTime":"0","endTime":"0","summary":"An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer  who received AFM24 at 480 mg weekly demonstrates that higher drug exposure  leads to improved objective response rate  and longer progression free survival   without a negative impact on safety. These findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24. MANNHEIM, Germany, April 29, 2025  -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager  AFM24, in patients with advanced or metastatic non-small cell lung cancer  in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research .The analysis is based on post-hoc exposure-response data from 72 NSCLC patients treated with 480 mg of AFM24 monotherapy or a combination of AFM24 with atezolizumab. F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/affimed-shows-higher-exposure-afm24-140000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFMD","BK4139","BK4195","BK4097","BK4211","OS","BK4181","ORR","PFS","PK","BK4218"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":118,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}